Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROGAINE EXTRA STRENGTH (FOR MEN) vs ROGAINE (FOR WOMEN)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation. It also prolongs the anagen phase of hair follicles and increases hair follicle size, promoting hair growth.
Minoxidil is a potassium channel opener. It causes vasodilation by opening ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of arteriolar smooth muscle. This improves blood flow to hair follicles and prolongs the anagen phase of hair growth, possibly by increasing vascular endothelial growth factor (VEGF) and other growth factors.
Treatment of androgenetic alopecia (male pattern baldness) in men
FDA-approved: Treatment of female androgenetic alopecia (female pattern hair loss) in women aged 19-49 years with mild to moderate hair loss,Off-label: Treatment of male pattern baldness (off-label for women if used for this purpose), alopecia areata, and other forms of hair thinning
1 m L of 5% minoxidil solution applied topically to the scalp twice daily.
Apply 1 m L of 2% minoxidil solution topically to the scalp twice daily (total 2 m L per day).
Terminal elimination half-life is approximately 4.2 hours (range 3.5–5.0 hours) in healthy adults. Clinical context: Maintains steady-state concentrations with twice-daily topical application without significant accumulation.
The terminal elimination half-life of minoxidil is approximately 4.2 hours (range 2–7 hours) following topical application, but the pharmacodynamic half-life (duration of drug presence in the skin and hair follicle) is longer, estimated at 24 hours. For oral minoxidil, the terminal half-life averages 4.5 hours (range 3–7 hours).
Minoxidil is primarily metabolized by conjugation with glucuronic acid at the N-oxide position in the liver. CYP450 enzymes are minimally involved.
Minoxidil is primarily metabolized in the liver via glucuronidation to minoxidil glucuronide, which is inactive. Minor metabolism via sulfation may occur. The metabolism is mediated by UDP-glucuronosyltransferases (UGTs).
Renal excretion of unchanged drug and metabolites accounts for approximately 95% of elimination. Fecal excretion is minimal (<3%).
Renal excretion of unchanged minoxidil and its glucuronide conjugates accounts for approximately 95% of the absorbed dose; about 5% is eliminated unchanged in feces via biliary excretion.
Approximately 20% bound to plasma proteins (primarily albumin).
Minoxidil is approximately 20% bound to serum proteins, primarily albumin, with negligible binding to alpha-1-acid glycoprotein.
Apparent volume of distribution is approximately 2.5 L/kg, indicating extensive distribution into total body water and tissues.
The apparent volume of distribution for minoxidil is 3.5 L/kg (range 2.5–4.5 L/kg), indicating extensive extravascular distribution and tissue binding, particularly to vascular smooth muscle.
Topical: systemic bioavailability is low (approximately 1.4% of applied dose) due to poor percutaneous absorption. Oral: approximately 50% (not indicated for this formulation).
Absolute bioavailability of topical minoxidil is approximately 1.5% (range 0.3–3.2%) of the applied dose, due to low percutaneous absorption and extensive first-pass metabolism in the skin. Oral minoxidil has an absolute bioavailability of 90%.
No dosage adjustment required for renal impairment; not systemically absorbed in significant amounts.
No dosage adjustment required for renal impairment.
No dosage adjustment required for hepatic impairment; not systemically absorbed in significant amounts.
No dosage adjustment required for hepatic impairment.
Safety and effectiveness in pediatric patients under 18 years have not been established.
Safety and efficacy not established; use is not recommended.
No specific dosage adjustment; use with caution due to potential for increased systemic absorption from thinner skin.
No specific dose adjustment; use with caution due to potential increased sensitivity.
No FDA boxed warning.
None for topical minoxidil (Rogaine for Women). Oral minoxidil (not this formulation) carries a boxed warning for adverse cardiovascular effects.
Cardiovascular risks such as tachycardia, fluid retention, and pericardial effusion with topical use are rare but possible.,May cause hypotension if accidentally ingested.,Avoid contact with eyes and broken skin.,Discontinue if scalp irritation occurs.,Use with caution in patients with hypertension or underlying cardiovascular disease.
Systemic absorption can cause cardiovascular effects such as tachycardia, fluid retention, and hypotension (rare with topical use),May cause local skin reactions: irritation, redness, itching, or dryness,Potential for increased hair loss initially (shedding of telogen hairs) during first 2-6 weeks,Avoid contact with eyes, mucous membranes, and broken skin,Use caution in patients with underlying cardiovascular disease (angina, arrhythmias, heart failure),Discontinue if systemic side effects occur or if no improvement after 6 months
Hypersensitivity to minoxidil or any component of the formulation.,Concomitant use with other topical agents on the scalp.
Hypersensitivity to minoxidil or any component of the formulation,Use on broken, irritated, or sunburned scalp,Concomitant use with other topical agents that may increase absorption (e.g., corticosteroids, tretinoin),Relative: Pregnancy and breastfeeding (minoxidil is pregnancy category C; use only if benefit outweighs risk)
No known food interactions.
No clinically significant food interactions. Avoid excessive caffeine or stimulants as they may exacerbate anxiety or palpitations (rare systemic absorption).
Topical minoxidil (Rogaine Extra Strength) is minimally absorbed (approximately 1.4% of applied dose). Animal studies show no teratogenicity at systemic exposures up to 4 times the human dose. Human data are insufficient; risk is considered low but cannot be excluded. Use only if clearly needed during pregnancy. No specific trimester risks identified.
Topical minoxidil (Rogaine for Women) has limited human pregnancy data. Animal studies show no teratogenic effects at systemic exposures up to 5 times the human topical dose. Systemic absorption is minimal (<1.5%) with recommended topical use, but it is classified as pregnancy category C. First trimester: theoretical risk, avoid use. Second and third trimesters: minimal known risk but use only if clearly needed.
Minoxidil is excreted in human milk following oral administration; however, following topical application, systemic absorption is minimal (1.4%). The M/P ratio is unknown. Because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Minoxidil is excreted in human milk following oral administration; however, data after topical use are lacking. The milk-to-plasma ratio (M/P) is unknown for topical application. Due to potential for adverse effects in the nursing infant (e.g., hypotension), breastfeeding is not recommended during treatment.
No dose adjustment is necessary. Pharmacokinetic changes in pregnancy (e.g., increased blood volume, altered skin perfusion) are not expected to significantly alter the minimal systemic absorption of topical minoxidil. Use standard dosing: 1 m L twice daily to the scalp.
No dose adjustments are recommended based on pharmacokinetic changes in pregnancy, as systemic absorption is minimal. However, use during pregnancy is generally discouraged. If used, the standard dose (2% or 5% solution, 1 m L twice daily) should not be exceeded.
Rogaine Extra Strength (5% minoxidil) is indicated for androgenetic alopecia in men. Onset of hair regrowth typically occurs after at least 4 months of twice-daily use; continued use is required to maintain effects. Discontinue if scalp irritation or unwanted facial hair growth occurs. Not effective for receding frontal hairline; primarily promotes vertex balding. May cause initial shedding of telogen hairs, which is a sign of efficacy.
Minoxidil 5% foam is first-line for female pattern hair loss (FPHL). Response requires 4-6 months of consistent use; counsel patients not to expect immediate results. Initial shedding may occur in first 2-6 weeks due to telogen effluvium; this is a positive sign of drug activity. Discontinue if scalp irritation or hypertrichosis develops. Avoid use on broken or sunburned skin. Apply to dry scalp, not to hair shaft.
Apply 1 m L directly to the scalp in the affected area twice daily, not more often.,Wash hands thoroughly after each application.,Do not apply to wet hair or within 24 hours of using other scalp treatments.,Results may take 4 months or longer; continued use is necessary to maintain regrowth.,Initial hair shedding is normal and indicates new hair growth.,Avoid contact with eyes; if accidental contact occurs, rinse with cool water.
Apply 1/2 capful of foam to dry scalp once daily, no need to rinse.,Results take at least 4 months; continue use to maintain regrowth.,Initial hair shedding is temporary and normal.,Do not use if pregnant or breastfeeding.,Avoid contact with eyes; if contact occurs, rinse with cool water.,Wash hands after application.,Do not use on other body parts.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROGAINE EXTRA STRENGTH (FOR MEN) vs ROGAINE (FOR WOMEN), answered by our medical review team.
ROGAINE EXTRA STRENGTH (FOR MEN) is a Hair Growth Agent that works by Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation. It also prolongs the anagen phase of hair follicles and increases hair follicle size, promoting hair growth.. ROGAINE (FOR WOMEN) is a Hair Growth Agent that works by Minoxidil is a potassium channel opener. It causes vasodilation by opening ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of arteriolar smooth muscle. This improves blood flow to hair follicles and prolongs the anagen phase of hair growth, possibly by increasing vascular endothelial growth factor (VEGF) and other growth factors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROGAINE EXTRA STRENGTH (FOR MEN) and ROGAINE (FOR WOMEN) depend on the specific clinical indication. These are both Hair Growth Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROGAINE EXTRA STRENGTH (FOR MEN) is: 1 m L of 5% minoxidil solution applied topically to the scalp twice daily.. The standard adult dose of ROGAINE (FOR WOMEN) is: Apply 1 m L of 2% minoxidil solution topically to the scalp twice daily (total 2 m L per day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROGAINE EXTRA STRENGTH (FOR MEN) and ROGAINE (FOR WOMEN) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROGAINE EXTRA STRENGTH (FOR MEN) is classified as Category C. Topical minoxidil (Rogaine Extra Strength) is minimally absorbed (approximately 1.4% of applied dose). Animal studies show no teratogenicity at systemic exposures up to 4 times the. ROGAINE (FOR WOMEN) is classified as Category C. Topical minoxidil (Rogaine for Women) has limited human pregnancy data. Animal studies show no teratogenic effects at systemic exposures up to 5 times the human topical dose. Syste. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.